Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifetroban in Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059Phase 2Recruiting
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Ifetroban Sodium with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
ifetroban
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05571059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571059.